Company Overview

Novartis India Limited (NIL) operates in the Indian pharmaceutical market with focus on six anchor therapy areas: Cardiology, Pain Management, Women's Health, CNS, Transplant, and Ophthalmology. The company reported revenue CAGR of -2% and PAT CAGR of -3% from FY23-26, with net cash position of ₹668 crore as of latest reporting.

Strategic Initiatives

The company outlined a four-pillar strategic playbook:

1. Compounding equity and therapy expansion: Leveraging multi-decade prescriber loyalty across trusted, market-leading brands

2. Rigorous execution focus: Implementing dedicated, therapy-aligned field force delivering deep specialist coverage pan-India

3. Disciplined capital deployment: Maintaining asset-light model with dedicated M&A engine channeling capital to high-return growth

4. Strong Governance Framework: Independent board oversight, disciplined controls and experienced leadership team

Growth Initiatives

  • Strengthen focus on existing brands with 900+ member field force covering ~150,000 HCPs pan-India
  • Lifecycle management of mature brands through innovative distribution models and evidence-led medical engagement
  • Entry into attractive chronic therapies like cardio-metabolic therapy
  • Broadening reach within core therapies through new launches in fast-growing segments

M&A Transactions Announced

Minipress XL Acquisition:

  • Acquired rights to use 'Minipress' trademark from Pfizer Inc. for purchase consideration of ₹1,250 crore
  • Investment funded by combination of internal accruals and debt
  • Minipress is a market-leading MNC cardio brand with strong equity

Ophthalmic In-licensing:

  • Exclusive Distribution and Promotion Agreement with NHPL for retina portfolio
  • Products include Accentrix® (ranibizumab) and Pagenax® (brolucizumab)
  • Upfront consideration payable by NIL to NHPL: ₹10 crore
  • Pagenax® is patent-protected VEGF inhibitor for wAMD and DME indications
  • Accentrix® is VEGF inhibitor for wAMD, DME, diabetic retinopathy, RVO, and mCNV

Governance Framework

New Board Composition:

  • Ramesh Ramadurai: Chairperson, Independent Director (ex-Managing Director, 3M India)
  • Suchita Sharma: Independent Director (ex-Audit Partner, PwC), Chairperson of Audit Committee
  • Shashank Sinha: Independent Director (ex-MD & CEO, Strides Pharma), Chairperson of NRC
  • Dr. Vikas Gupta: Managing Director and CEO (ex-CEO at Alkem Laboratories)
  • Dr. Jagriti Gupta: Non-Executive Director (Advisor to ChrysCapital)
  • Kshitij Sheth: Non-Executive Director (Senior Vice President, ChrysCapital)
  • Unknown Director: MD, ChrysCapital (previously at Citigroup Global Capital Markets)

New Management Team:

  • Bhagwat Singh Deora: Chief Financial Officer (ex-VP Finance at JB Chemicals)
  • Jason D'Souza: President – M&A, BD & IR (ex-EVP, Head of IR & M&A at JB Chemicals)
  • Sumeet Rajput: President – Business Operations (ex-VP at Alkem Laboratories)
  • Masud Shaikh: Chief Supply Chain Officer (ex-SVP Distribution at Alembic)
  • Rahul Vijayvargiya: Chief Human Resources Officer (ex-Alkem, Reliance Retail, Glenmark, Pfizer)

Transition Plan and Financial Impact

Current State: Brands promoted and distributed through partner-led arrangement

Future State: NIL-owned brands taken to market by own field force and distribution network

Near-term Impact (FY27):

  • Upfront investment phase with field-force cost running ahead of current scale
  • One-time business impact in Q2-Q4 FY27 including cost of partnership termination agreement and sales returns from partner
  • These are transition effects, not changes in underlying demand

Structural Gains:

  • Brand ownership moves in-house (Voveran, Macalvit, Methergin now with NIL)
  • Full commercial independence for pricing, promotion, channel and lifecycle decisions
  • Dedicated field force focused solely on portfolio

Ownership Changes

  • ChrysCapital Group acquired 70.68% stake in NIL from Novartis AG
  • Open offer completed with tendering period June 11-24, 2026 at ₹860.64 per share
  • Very minimal shares tendered by public investors
  • ChrysCapital closed purchase on July 29, 2026
  • With Novartis AG exit as promoter, NIL plans to change name within 120 days subject to stakeholder approvals

ChrysCapital Background

  • Established in 1999, $8+ billion raised across PE and public markets funds
  • 110+ investments across sectors, 85+ exits
  • Currently investing out of its 10th fund with $2 billion+ total capital raised
  • Significant healthcare investments including leading CRDMO, derma company, diabetology medicines, and multiple branded pharma companies